Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 284,970
  • Shares Outstanding, K 27,140
  • Annual Sales, $ 1,520 K
  • Annual Income, $ -73,960 K
  • 60-Month Beta 2.44
  • Price/Sales 202.68
  • Price/Cash Flow N/A
  • Price/Book 6.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.47
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.52
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +32.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.32 +62.66%
on 01/30/20
11.33 -9.27%
on 02/20/20
+3.24 (+46.02%)
since 01/24/20
3-Month
6.32 +62.66%
on 01/30/20
11.33 -9.27%
on 02/20/20
+3.06 (+42.38%)
since 11/25/19
52-Week
4.52 +127.43%
on 03/22/19
11.33 -9.27%
on 02/20/20
+4.00 (+63.69%)
since 02/25/19

Most Recent Stories

More News
Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it...

SNDX : 10.28 (-2.10%)
Syndax Announces Participation at Two Upcoming Investor Conferences

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members...

SNDX : 10.28 (-2.10%)
Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).

SNDX : 10.28 (-2.10%)
Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has...

SNDX : 10.28 (-2.10%)
HTGC : 15.04 (-3.77%)
Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science...

SNDX : 10.28 (-2.10%)
Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a strategic...

SNDX : 10.28 (-2.10%)
Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it...

SNDX : 10.28 (-2.10%)
Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the publication...

SNDX : 10.28 (-2.10%)
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 10.28 (-2.10%)
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 10.28 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade SNDX with:

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

2nd Resistance Point 11.03
1st Resistance Point 10.65
Last Price 10.28
1st Support Level 9.95
2nd Support Level 9.63

See More

52-Week High 11.33
Last Price 10.28
Fibonacci 61.8% 8.73
Fibonacci 50% 7.93
Fibonacci 38.2% 7.12
52-Week Low 4.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar